马吲哚、二甲双胍联合治疗腹型肥胖的临床研究

The Clinical Study of Mazindol and Metformin in the Treatment of Abdominal Obesity

目的:探讨联合运用马吲哚、二甲双胍治疗腹型肥胖的临床价值。方法:对120例腹型肥胖患者,随机分成二甲双胍治疗组、马吲哚治疗组和二甲双胍、马吲哚联合治疗组,分别测定各组治疗前后的体重指数(BMI)腰围/臀围、血TG、CHOL、HDLF、INS,比较各组对腹型肥胖治疗效果的差异。结果:①马吲哚、二甲双胍及联合治疗三组间治疗后的体重、BMI、腰围/臀围较治疗前均有明显下降(P<0.05);其中联合用药组较单独有药各组下降更为明显(P<0.05)。②治疗后各组的TG、CHOL及FINS均有下降,HDL有缓慢上升(P<0.05),而联合用药组与其它两组相比改善更显著(P<0.05)。结论:二甲双胍、马吲哚联合治疗可以改善胰岛素抵抗,对腹型肥胖疗效确切,具有较好的临床实用价值。

Objective： To study the clinical value of Mazindol and Metformin in the treatment of abdominal obesity. Methods： One hundred and twenty abdominal obesity patients were assigned to Mazindol, Metformin and combined treatment group, The weight, BMI, WHR, TG, CHOL, HDL and fasting insulin （FINS） of the patients in three groups were measured before and after treatment. The changes in different groups were compared. Results： ①After treatment, the weight, BMI and WHR significantly decreased （P〈0.05） in three groups. The decrease in combined treatment group was more significant than other one, ② After treatment, TG, CHOL and FINS significantly decreased （P〈0.05）, HDL rose （P〈0.05） in three groups, But the changes in the combined treatment group were more significant. Conclusions： The combined treatment of Mazindol and Metformin can improve the insulin resistanee（IR ） and has an effective treatment to abdominal obesity. It has a clinical and practical value,